Good day and welcome to the Stifel Financial fourth quarter financial results conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr ...

(RTTNews) - Stifel Financial Corp. (SF) revealed earnings for its fourth quarter that increased from last year and beat the Street estimates. The company's earnings totaled $234.69 million ...

Stifel noted that Reuters reported this morning that Japan’s NEC is considering making a bid for CSG Systems (CSGS) and that talks between the two are in “early stages.” NEC owns Netcracker ...

Stifel Financial Corp. announced a cash dividend of $0.46 per share on its common stock, payable on March 17, 2025, to shareholders recorded by March 3, 2025. Additionally, the company declared ...

Stifel Financial (SF) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $1.97 per share. This compares to earnings of $1.50 per share a year ago.

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

Stifel Financial Corp. provides securities brokerage, investment banking, trading, investment advisory and related financial services. It operates through the following segments: Global Wealth ...

THE SCOOP Home to the largest industrial complexes in the Northeast and the Eagles high school teams, Hauppauge is both a thriving business center and a cozy community big on school achievements.

Thursday, January 23, 2025, marks the release of a new report by Stifel analysts on the US transport sector. The report outlines a cautious perspective on the industry's future, noting that while ...

On January 31, Stifel reduced Intel’s price target from $25 to $21 while maintaining a Hold rating. The firm noted that although Q4 results exceeded expectations, Q1 guidance fell short.

On Tuesday, Stifel analysts reiterated their Buy rating on International Game Technology (NYSE:IGT) with a steady price target of $26.00, well within the broader analyst range of $22-$35.